Promising Research
New drug combination found for rare form of cancer
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Waldenström macroglobulinemia (WM), a rare form of lymphoma, does not have any
known cure and only one FDA-approved treatment, making it challenging to treat
patients. But with the work being done at UNH, that may one day change.
Researchers have taken the novel approach of targeting specific cell proteins that
control DNA information using inhibitors, or drugs, that were effective in reducing the
growth of the cancer cells and when combined with a third drug were even more
successful in killing the WM cancer cells, which could lead to more treatment options.

“This is the first study to report the promising results of inhibitors in Waldenström
macroglobulinemia which could open the door to new clinical possibilities,” said Sherine
Elsawa, associate professor of molecular, cellular and biomedical sciences. “We know
that targeting these types of proteins with inhibitors can increase high therapeutic
results in many other kinds of cancer but desired results in WM cells has been lacking.”
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In their study, just published in the journal Epigenomics, Elsawa and her team focused
on the epigenetic regulation of WM cancer cells. Epigenetics is the study of how DNA is
opened and closed to allow certain genes to be expressed or encoded. Each protein
has a different function—some write the genetic code, some read or interpret it and
others can erase the code. The researchers focused on two proteins, bromodomain and
extraterminal (BET), which are epigenetic readers. BET proteins have been shown to be
involved in pathological conditions including cancer. Drugs that inhibit these proteins
can block gene expression that regulate cancer cells by slowing and stopping their
growth.
The WM cancer cells were treated with the BET inhibitors JQ-1 and I-BET-762 which
reduced the growth of the WM cells in the lab. While the dose dependent effect was
significant for both drugs, JQ-1 showed the strongest inhibitory effect with 70%
reduction in cell proliferation at the highest dose. However, neither inhibitor was
effective in inducing cell death.
Researchers tried adding three different drugs, venetoclax, panabinostat and ibrutinib
(the only FDA approved therapy specifically for WM patients), one at a time in
combination with the BET inhibitors ((JQ-1 and I-BET-762). After studying each
separate drug combination, they found that adding venetoclax or panabinostat to the
inhibitors was more effective than adding ibrutinib—with panobinostat offering the
greatest combination therapy. Although ibrutinib alone has shown efficacy in WM
patients, the study suggests epigenetic targeting is likely to provide a better therapeutic
outcome and WM patients undergoing ibrutinib therapy may benefit from the addition of
JQ1 which may enhance the efficacy of ibrutinib.
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